Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138916 · ClinicalTrials.gov registry record · Phase 3
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,656
- Enrollment target
NCT02138916: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02138916 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,656 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02138916, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,656 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
Primary Outcome
A COPD exacerbation is defined by symptomatic worsening of COPD requiring: * Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or * Use of antibiotics; and/or * An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment peri
Interventions
- DRUG Placebo
- DRUG Benralizumab Arm A
- DRUG Benralizumab Arm B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,656 participants |
| Start Date | 2014-06-13 |
| Est. Completion | 2018-04-10 |
| Phase | Phase 3 |
What the finished NCT02138916 record still lists
NCT02138916 is an interventional study that assigns participants to a tested intervention. Its 1,656 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02138916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02138916 about?
NCT02138916 is a clinical study titled "Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History". The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
What is the current status of trial NCT02138916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,656 participants. The study started on 2014-06-13. Estimated completion is 2018-04-10.
What interventions are being tested in trial NCT02138916?
The interventions under investigation include: Placebo (DRUG), Benralizumab Arm A (DRUG), Benralizumab Arm B (DRUG).
Who is sponsoring clinical trial NCT02138916?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02138916's enrollment target sits among peer trials
1,656 137th of 2000 higher than 1,863 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI